Search

Your search keyword '"Lora, David"' showing total 156 results
Start Over Author "Lora, David" Search Limiters Full Text
156 results on '"Lora, David"'

1. Immunogenicity of a third dose with mRNA-vaccines in the ChAdOx1-S/BNT162b2 vaccination regimen against SARS-CoV-2 variants

Author

García, Lucía Díaz, García, Elena Ramírez, Meseguer, Enrique Seco, Stewart Balbàs, Stefan Mark, Candón, Alicia Marín, García, Irene García, Elizalde, Mikel Urroz, Rosa, Paula de la, García, Marta Sanz, Crespo, Cristina López, Martínez, Vega Mauleón, de Madariaga Castell, Raquel, Vara, Laura Vitón, Prieto-Pérez, Rocío, Vargas-Castrillón, Emilio, Laredo, Leonor, Zhu-Huang, Ouhao, Iglesias, Teresa, Imaz-Ayo, Natale, Meijide, Susana, García de Vicuña, Aitor, Santorcuato, Ana, Exposito, Iraide, de Benito, Sara, Bustinza, Alazne, Gallego, Mikel, García-Vázquez, Dolores, Belén de la Hoz, Ana, Pérez-Nanclares, Gustavo, Aurrekoetxea, Josu, Urrutia, Ines, Martínez-Salazar, Rosa, Orcajo, Janire, Calvo, Begoña, Corcuera, June, Velasco, Olaia, Aguayo, Anibal, Martínez-Gómez, Xavier, Otero-Romero, Susana, Armadans, Lluis, Borras-Bermejo, Blanca, Parés, Oleguer, Uriona, Sonia, Rodrigo Pendás, José Ángel, Llorente, Cesar, Santos, José, Pinós, Laia, Camacho, Lina, Riera, Judith, Sans, Carla, Agustí, Antonia, Altadill, Carmen, Blancafort, Carla Aguilar, Serrat, Gisela Gili, Plaza, Aitana, Prius, Anna Feliu, Torrens, Maria Margarita, Palacio, Esther, Torres, Gloria, Calonge, Julia, Alins, Elena Ballarin, Pérez-Esquirol, Eulàlia, Bosch, Lourdes Vendrell, Aldea, Marta, Mellado, Eugènia, Marcos, M<ce:sup loc='post">a</ce:sup> Ángeles, Tortajada, Marta, Barón-Mira, Lourdes E., Granés, Laura, Lazaar, Sulayman, Herranz, Sara, Malet, Montserrat, Quesada, Sebastiana, Llupià, Anna, Olivé, Victoria, Trilla, Antoni, Gómez, Begoña, González, Elisenda, Romero, Sheila, Gámez, Francisco Javier, Casals, Cristina, Burunat, Laura, Castelló, Juan José, Fernández, Patricia, Bedini, Josep Lluís, Vila, Jordi, Hurtado, Juan Carlos, Jado, Isabel, Fedele, Giovanni, Perea, Concepción, González, Mónica, Grajera, Isabel, Murillo, María Ángeles, Balfagón, Pilar, Díaz-Marín, Irene, González-Pardo, Gema, García-Pérez, Javier, Borobia, Alberto M., Pérez-Olmeda, Mayte, Portolés, Antonio, Castaño, Luis, Campins-Artí, Magdalena, Bertrán, María Jesús, Bermejo, Mercedes, Arribas, José Ramón, López, Andrea, Ascaso-del-Rio, Ana, Arana-Arri, Eunate, Fuentes Camps, Inmaculada, Vilella, Anna, Cascajero, Almudena, García-Morales, María Teresa, Castillo de la Osa, María, Pérez Ingidua, Carla, Lora, David, Jiménez-Santana, Paloma, Pino-Rosa, Silvia, Gómez de la Cámara, Agustín, De La Torre-Tarazona, Erick, Calonge, Esther, Cruces, Raquel, Belda-Iniesta, Cristóbal, Alcamí, José, Frías, Jesús, Carcas, Antonio J., and Díez-Fuertes, Francisco

Published
2024
Full Text
View/download PDF

2. No changes in hemostasis after COVID-19–heterologous vaccination schedule: A subanalysis of the phase 2 CombiVacS study

Author

Butta, Nora V., Arias-Salgado, Elena G., Monzón Manzano, Elena, Acuña, Paula, Álvarez Román, María Teresa, Buño-Soto, Antonio, Ramos Ramos, Juan Carlos, Belda-Iniesta, Cristóbal, Frías, Jesús, Carcas, Antonio J., de Soto, Lucía Martínez, de Miguel Buckley, Rosa, Lora, David, García-Morales, María Teresa, Borobia, Alberto M., Arribas, José Ramón, and Jiménez Yuste, Víctor

Published
2023
Full Text
View/download PDF

3. Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study

Author

García-Pérez, Javier, González-Pérez, María, Castillo de la Osa, María, Borobia, Alberto M., Castaño, Luis, Bertrán, María Jesús, Campins, Magdalena, Portolés, Antonio, Lora, David, Bermejo, Mercedes, Conde, Patricia, Hernández-Gutierrez, Lourdes, Carcas, Antonio, Arana-Arri, Eunate, Tortajada, Marta, Fuentes, Inmaculada, Ascaso, Ana, García-Morales, María Teresa, Erick de la Torre-Tarazona, Humberto, Arribas, José-Ramón, Imaz-Ayo, Natale, Mellado-Pau, Eugènia, Agustí, Antonia, Pérez-Ingidua, Carla, Gómez de la Cámara, Agustín, Ochando, Jordi, Belda-Iniesta, Cristobal, Frías, Jesús, Alcamí, José, and Pérez-Olmeda, Mayte

Published
2022
Full Text
View/download PDF

5. Role of cytomegalovirus infection after kidney transplantation on the subsequent risk of atherosclerotic and thrombotic events

Author

Rodríguez-Goncer, Isabel, Corbella, Laura, Lora, David, Redondo, Natalia, López-Medrano, Francisco, Gutiérrez, Eduardo, Sevillano, Ángel, Hernández Vicente, Ana, San-Juan, Rafael, Ruiz-Merlo, Tamara, Parra, Patricia, González, Esther, Folgueira, Maria Dolores, Andrés, Amado, Aguado, José María, and Fernández-Ruiz, Mario

Published
2022
Full Text
View/download PDF

6. Derivation and external validation of the SIMPLICITY score as a simple immune-based risk score to predict infection in kidney transplant recipients

Author

Fernández-Ruiz, Mario, Seron, Daniel, Alonso, Ángel, Lora, David, Hernández, Domingo, González, Esther, Pérez-Sáez, María José, Gómez, Gonzalo, Pallardó-Mateu, Luis Manuel, Jimeno-García, Luisa, Cofán, Frederic, Gutierrez-Dalmau, Alex, Ruiz, Juan Carlos, Ramírez-Puga, Ana, Santana Estupiñán, Raquel, Marcén, Roberto, Portolés, José María, Muñoz-Cepeda, Miguel Ángel, López-Medrano, Francisco, San Juan, Rafael, Andrés, Amado, and Aguado, José María

Published
2020
Full Text
View/download PDF

10. Evaluation of the effectiveness and safety of oral vancomycin versus placebo in the prevention of recurrence ofClostridioides difficileinfection in patients under systemic antibiotic therapy: a phase III, randomised, double-blind clinical trial

Author

San-Juan, Rafael, primary, Origuen, Julia, additional, Campion, Karen, additional, Fernández-Ruiz, Mario, additional, Diaz-Pollan, Beatriz, additional, Callejas-Diaz, Alejandro, additional, Candela, Giancarlo, additional, Orellana, Maria Angeles, additional, Lora, David, additional, Llorente Muñoz, Irene, additional, Garcia, Maria Teresa, additional, Martinez-Uña, Maite, additional, Ferrari, Jose Miguel, additional, and Aguado, Jose M, additional

Published
2023
Full Text
View/download PDF

12. How, when, and to what degree do people with alcohol dependence recover their psychological wellbeing and quality of life? The Madrid Recovery Project

Author

Rubio, Gabriel, Esteban Rodríguez, Laura, Sion, Ana, Ramis Vidal, Lilian, Blanco, María J., Zamora-Bayon, Amelia, Caba-Moreno, Marta, Macias-Molina, Ana I., Pérez-Sánchez, Dolores, Rubio-Escobar, Enrique, Ruiz-Diez, Joaquín, Marin, Marta, Arias, Francisco, Lora, David, and Jurado-Barba, Rosa

Subjects
Psychiatry and Mental health
Published
2023
Full Text
View/download PDF

13. Characteristics of clinical trials of influenza and respiratory syncytial virus registered in ClinicalTrials.gov between 2014 and 2021

Author

Instituto de Salud Carlos III, European Commission, Lora, David, García-Reyne, Ana, Lalueza, Antonio, Maestro-de la Calle, Guillermo, Ruiz-Ruigómez, María, Calderón, Enrique J., Menéndez-Orenga, Miguel, Instituto de Salud Carlos III, European Commission, Lora, David, García-Reyne, Ana, Lalueza, Antonio, Maestro-de la Calle, Guillermo, Ruiz-Ruigómez, María, Calderón, Enrique J., and Menéndez-Orenga, Miguel

Abstract

The randomized clinical trial (RCT) is the ideal and mandatory type of study to verify the effect and safety of a drug. Our aim is to examine the fundamental characteristics of interventional clinical trials on influenza and respiratory syncytial virus (RSV). This is a cross-sectional study of RCTs on influenza and RSV in humans between 2014 and 2021 registered in ClinicalTrials.gov. A total of 516 studies were identified: 94 for RSV, 423 for influenza, and 1 for both viruses. There were 51 RCTs of RSV vaccines (54.3%) and 344 (81.3%) for influenza virus vaccines (p < 0.001). Twelve (12.8%) RCTs for RSV were conducted only with women, and 6 were conducted only with pregnant women; for RCTs for influenza, 4 (0.9%) and 3, respectively. For RSV, 29 (31%) of the RCTs were exclusive to people under 5 years of age, and 21 (5%) for influenza virus (p < 0.001). For RSV, there are no RCTs exclusively for people older than or equal to 65 years and no phase 4 trials. RCTs on influenza virus and RSV has focused on vaccines. For the influenza virus, research has been consolidated, and for RSV, research is still in the development phase and directed at children and pregnant women.

Published
2023

14. No changes in haemostasis after COVID-19-heterologous vaccination schedule: a sub analysis of the phase 2 CombiVacS study

Author

Butta, Nora V., primary, Arias-Salgado, Elena G., additional, Manzano, Elena Monzón, additional, Acuña, Paula, additional, Álvarez Román, María Teresa, additional, Buño-Soto, Antonio, additional, Ramos Ramos, Juan Carlos, additional, Belda-Iniesta, Cristóbal, additional, Frías, Jesús, additional, Carcas, Antonio J., additional, Martínez de Soto, Lucía, additional, de Miguel Buckley, Rosa, additional, Lora, David, additional, García-Morales, María Teresa, additional, Borobia, Alberto M., additional, Arribas, José Ramón, additional, and Yuste, Víctor Jiménez, additional

Published
2023
Full Text
View/download PDF

15. Whole-body imaging of lymphovascular niches identifies pre-metastatic roles of midkine

Author

Olmeda, David, Cerezo-Wallis, Daniela, Riveiro-Falkenbach, Erica, Pennacchi, Paula C., Contreras-Alcalde, Marta, Ibarz, Nuria, Cifdaloz, Metehan, Catena, Xavier, Calvo, Tonantzin G., Can, Estela, Alonso-Curbelo, Direna, Suarez, Javier, Osterloh, Lisa, Graa, Osvaldo, Mulero, Francisca, Megas, Diego, Caamero, Marta, Martnez-Torrecuadrada, Jorge L., Mondal, Chandrani, Di Martino, Julie, Lora, David, Martinez-Corral, Ins, Bravo-Cordero, J. Javier, Muoz, Javier, Puig, Susana, Ortiz-Romero, Pablo, Rodriguez-Peralto, Jos L., Ortega, Sagrario, and Soengas, Mara S.

Subjects
Melanoma -- Physiological aspects, Cancer metastasis -- Observations, Environmental issues, Science and technology, Zoology and wildlife conservation
Abstract

Author(s): David Olmeda [1]; Daniela Cerezo-Wallis [1]; Erica Riveiro-Falkenbach [2]; Paula C. Pennacchi [1]; Marta Contreras-Alcalde [1]; Nuria Ibarz [3]; Metehan Cifdaloz [1]; Xavier Catena [1]; Tonantzin G. Calvo [1]; [...]

Published
2017
Full Text
View/download PDF

16. Additional file 1 of Sample size requirement in trials that use the composite endpoint major adverse cardiovascular events (MACE): new insights

Author

Marsal, Josep Ramon, Urreta-Barallobre, Iratxe, Ubeda-Carrillo, Marimar, Osorio, Dimelza, Lumbreras, Blanca, Lora, David, Fernández-Felix, Borja M., Oristrell, Gerard, Ródenas-Alesina, Eduard, Herrador, Lorena, Ballesteros, Mónica, Zamora, Javier, Pijoan, Jose I., Ribera, Aida, and Ferreira-González, Ignacio

Abstract

Additional file 1: Supplementary material.

Published
2023
Full Text
View/download PDF

18. Serum GDF-15 Levels Accurately Differentiate Patients with Primary Mitochondrial Myopathy, Manifesting with Exercise Intolerance and Fatigue, from Patients with Chronic Fatigue Syndrome.

Author

Bermejo-Guerrero, Laura, de Fuenmayor-Fernández de la Hoz, Carlos Pablo, Guerrero-Molina, María Paz, Martín-Jiménez, Paloma, Blázquez, Alberto, Serrano-Lorenzo, Pablo, Lora, David, Morales-Conejo, Montserrat, González-Martínez, Irene, López-Jiménez, Elena Ana, Martín, Miguel A., and Domínguez-González, Cristina

Subjects
CHRONIC fatigue syndrome, FATIGUE (Physiology), MITOCHONDRIA, MELAS syndrome, MITOCHONDRIAL pathology, MUSCLE diseases
Abstract

Primary mitochondrial myopathies (PMM) are a clinically and genetically highly heterogeneous group that, in some cases, may manifest exclusively as fatigue and exercise intolerance, with minimal or no signs on examination. On these occasions, the symptoms can be confused with the much more common chronic fatigue syndrome (CFS). Nonetheless, other possibilities must be excluded for the final diagnosis of CFS, with PMM being one of the primary differential diagnoses. For this reason, many patients with CFS undergo extensive studies, including extensive genetic testing and muscle biopsies, to rule out this possibility. This study evaluated the diagnostic performance of growth differentiation factor-15 (GDF-15) as a potential biomarker to distinguish which patient with chronic fatigue has a mitochondrial disorder. We studied 34 adult patients with symptoms of fatigue and exercise intolerance with a definitive diagnosis of PMM (7), CFS (22), or other non-mitochondrial disorders (5). The results indicate that GDF-15 can accurately discriminate between patients with PMM and CFS (AUC = 0.95) and between PMM and patients with fatigue due to other non-mitochondrial disorders (AUC = 0.94). Therefore, GDF-15 emerges as a promising biomarker to select which patients with fatigue should undergo further studies to exclude mitochondrial disease. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

21. Plasma Gelsolin Reinforces the Diagnostic Value of FGF-21 and GDF-15 for Mitochondrial Disorders

Author

Peñas, Ana, primary, Fernández-De la Torre, Miguel, additional, Laine-Menéndez, Sara, additional, Lora, David, additional, Illescas, María, additional, García-Bartolomé, Alberto, additional, Morales-Conejo, Montserrat, additional, Arenas, Joaquín, additional, Martín, Miguel A., additional, Morán, María, additional, Domínguez-González, Cristina, additional, and Ugalde, Cristina, additional

Published
2021
Full Text
View/download PDF

22. Potential Role of Natriuretic Response to Furosemide Stress Test During Acute Heart Failure

Author

Caravaca Pérez, Pedro, primary, Nuche, Jorge, additional, Morán Fernández, Laura, additional, Lora, David, additional, Blázquez-Bermejo, Zorba, additional, López-Azor, Juan Carlos, additional, de Juan Bagudá, Javier, additional, García-Cosío Carmena, María Dolores, additional, Escribano Subías, Pilar, additional, Salguero-Bodes, Rafael, additional, Arribas Ynsaurriaga, Fernando, additional, and Delgado, Juan F., additional

Published
2021
Full Text
View/download PDF

23. Presence of Extra-Criteria Antiphospholipid Antibodies Is an Independent Risk Factor for Ischemic Stroke

Author

Naranjo, Laura, primary, Ostos, Fernando, additional, Gil-Etayo, Francisco Javier, additional, Hernández-Gallego, Jesús, additional, Cabrera-Marante, Óscar, additional, Pleguezuelo, Daniel Enrique, additional, Díaz-Simón, Raquel, additional, Cerro, Mercedes, additional, Lora, David, additional, Martínez-Salio, Antonio, additional, and Serrano, Antonio, additional

Published
2021
Full Text
View/download PDF

24. Tumor mutational burden assessment in non-small-cell lung cancer samples: results from the TMB2 harmonization project comparing three NGS panels

Author

Ramos-Paradas, Javier, primary, Hernández-Prieto, Susana, additional, Lora, David, additional, Sanchez, Elena, additional, Rosado, Aranzazu, additional, Caniego-Casas, Tamara, additional, Carrizo, Nuria, additional, Enguita, Ana Belén, additional, Muñoz-Jimenez, María Teresa, additional, Rodriguez, Borja, additional, Perez-Gonzalez, Urbicio, additional, Gómez-Sánchez, David, additional, Ferrer, Irene, additional, Ponce Aix, Santiago, additional, Nuñez Buiza, Ángel, additional, Garrido, Pilar, additional, Palacios, José, additional, Lopez-Rios, Fernando, additional, Garrido-Martin, Eva M, additional, and Paz-Ares, Luis, additional

Published
2021
Full Text
View/download PDF

28. The Value of PD-L1 Expression as Predictive Biomarker in Metastatic Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials

Author

Carretero-González, Alberto, primary, Lora, David, additional, Martín Sobrino, Isabel, additional, Sáez Sanz, Irene, additional, Bourlon, María T., additional, Anido Herranz, Urbano, additional, Martínez Chanzá, Nieves, additional, Castellano, Daniel, additional, and de Velasco, Guillermo, additional

Published
2020
Full Text
View/download PDF

31. Systematic review and meta-analysis comparing Adjustable Transobturator Male System (ATOMS) and Adjustable Continence Therapy (ProACT) for male stress incontinence

Author

Angulo Cuesta, Javier, Schönburg, Sandra, Giammò, Alessandro, Abellán, Francisco J., Arance Gil, José Ignacio, and Lora, David

Subjects
Neoplasias de la próstata, Urología, Cáncer, Tecnología médica, Incontinencia urinaria
Abstract

Background and purpose: Urinary incontinence is one of the most serious complications of prostate cancer treatment. The objective of this study was to assess efficacy and safety of Adjustable Transobturator Male System (ATOMS) compared to Adjustable Continence Therapy (proACT) for male stress urinary incotinence according to literature findings. Material and methods: A systematic review and meta-analysis on adjustable devices ATOMS and ProACT is presented. Studies on female or neurogenic incontinence were excluded. Differences between ATOMS and proACT in primary objective: dryness status (no-pad or one safety pad/day) after initial device adjustment, and in secondary objectives: improvement, satisfaction, complications and device durability, were estimated using random-effect model. Statistical heterogeneity among studies included in the meta-analysis was assessed using tau2, Higgins´s I2 statistics and Cochran´s Q test. Results: Combined data of 41 observational studies with 3059 patients showed higher dryness (68 vs. 55%; p = .01) and improvement (91 vs. 80%; p = .007) rate for ATOMS than ProACT. Mean pad-count (-4 vs. -2.5 pads/day; p = .005) and pad-test decrease (-425.7 vs. -211.4 cc; p < .0001) were also significantly lower. Satisfaction was higher for ATOMS (87 vs. 56%; p = .002) and explant rate was higher for proACT (5 vs. 24%; p < .0001). Complication rate for ProACT was also higher, but not statistically significant (17 vs. 26%; p = .07). Mean follow-up was 25.7 months, lower for ATOMS than ProACT (20.8 vs. 30.6 months; p = .02). The rate of working devices favoured ATOMS at 1-year (92 vs. 76; p < .0001), 2-years (85 vs. 61%; p = .0008) and 3-years (81 vs. 58%; p = .0001). Significant heterogeneity was evidenced, due to variable incontinence severity baseline, difficulties for a common reporting of complications, different number of adjustments and time of follow-up and absence of randomized studies. Conclusions: Despite the limitations that studies available are exclusively descriptive and the follow-up is limited, literature findings confirm ATOMS is more efficacious, with higher patient satisfaction and better durability than ProACT to treat male stress incontinence. Sin financiación 2.740 JCR (2019) Q2, 27/71 Multidisciplinary Sciences 1.023 SJR (2019) Q1, 10/148 Multidisciplinary No data IDR 2019 UEM

Published
2019

32. Potential Role of Natriuretic Response to Furosemide Stress Test During Acute Heart Failure.

Author

Pérez, Pedro Caravaca, Nuche, Jorge, Fernández, Laura Morán, Lora, David, Blázquez-Bermejo, Zorba, López-Azor, Juan Carlos, de Juan Bagudá, Javier, García-Cosío Carmena, María Dolores, Subías, Pilar Escribano, Salguero-Bodes, Rafael, Ynsaurriaga, Fernando Arribas, and Delgado, Juan F.

Abstract

Poor natriuresis has been associated with a poorer response to diuretic treatment and worse prognosis in acute heart failure. Recommendations on how and when to measure urinary sodium (UNa) are lacking. We aim to evaluate UNa quantification after a furosemide stress test (FST) capacity to predict appropriate decongestion during acute heart failure hospitalization. METHODS: Patients underwent an FST on day-1 of admission, and UNa was measured 2 hours after, dividing patients into low or high UNa based on the sample median value. A semiquantitative composite congestive score (CCS; 0–9) and NT pro-BNP (N-terminal pro-B-type natriuretic peptide) quantification were assessed before the FST and at day 5 after the FST. RESULTS: Median UNa after FST in the 65 patients included was 113 (97–122) mmol/L. At day 5, a lower proportion of patients with a low UNa reached a 30% decrease in NT-proBNP levels (21 [66%] for low UNa versus 31 [94%] for high UNa; P=0.005) and an appropriate grade of decongestion (CCS<3) (20 [62%] for low UNa versus 32 [97%] for high UNa; P<0.001). A UNa>83 mmol/L 2 hours after FST had a 96% sensitivity to predict an NT-proBNP reduction ≥30% and 95% to predict a CCS<3 at day 5. Low UNa patients presented a lower cumulative diuresis and weight loss and presented more often with prolonged hospitalization, worsening heart failure, and readmission because of acute heart failure or death at 6 months. CONCLUSIONS: Low natriuresis after an FST identified patients at a higher risk of an inadequate diuretic response and an inappropriate decongestion. FST-guided diuretic treatment might help to improve decongestion, shorten hospitalizations, and to reduce adverse outcomes. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

34. Development of a predictive model of hospitalization in primary care patients with heart failure

Author

García-Olmos, Luis, Aguilar, Río, Lora, David, Carmona, Montse, Alberquilla, Ángel, García-Caballero, Rebeca, Sánchez Gómez, Luis, The Chic Group, UAM. Departamento de Medicina, Instituto de Investigación del Hospital de La Princesa (IP), Instituto de Salud Carlos III, and Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)

Subjects
Male, Pulmonology, Pérdida de la salud, Emotions, Social Sciences, 030204 cardiovascular system & hematology, Logistic regression, Endocrinology, Mathematical and Statistical Techniques, 0302 clinical medicine, Quality of life, Risk Factors, Medicine and Health Sciences, Psychology, Medicine, Prospective Studies, 030212 general & internal medicine, Prospective cohort study, COPD, Multidisciplinary, Statistics, Models, Cardiovascular, Middle Aged, Hospitals, Hospitalization, Physical Sciences, Hospitalizaciones, Female, Pacientes, Research Article, Cohort study, medicine.medical_specialty, Endocrine Disorders, Medicina, Science, Chronic Obstructive Pulmonary Disease, Cardiology, Research and Analysis Methods, 03 medical and health sciences, Diabetes mellitus, Diabetes Mellitus, Humans, Statistical Methods, Aged, Heart Failure, Hospitalizations, Primary Health Care, business.industry, Biology and Life Sciences, Métodos de obsevación, medicine.disease, Health Care, Clinical trial, Health Care Facilities, Metabolic Disorders, Heart failure, Emergency medicine, Quality of Life, Pacientes riesgo hospitalización, business, Mathematics, Forecasting
Abstract

Background Heart failure (HF) is the leading cause of hospitalization in people over age 65. Predictive hospital admission models have been developed to help reduce the number of these patients. Aim To develop and internally validate a model to predict hospital admission in one-year for any non-programmed cause in heart failure patients receiving primary care treatment. Design and setting Cohort study, prospective. Patients treated in family medicine clinics. Methods Logistic regression analysis was used to estimate the association between the predictors and the outcome, i.e. unplanned hospitalization over a 12-month period. The predictive model was built in several steps. The initial examination included a set of 31 predictors. Bootstrapping was used for internal validation. Results The study included 251 patients, 64 (25.5%) of whom were admitted to hospital for some unplanned cause over the 12 months following their date of inclusion in the study. Four predictive variables of hospitalization were identified: NYHA class III-IV, OR (95% CI) 2.46 (1.23–4.91); diabetes OR (95% CI) 1.94 (1.05–3.58); COPD OR (95% CI) 3.17 (1.45–6.94); MLHFQ Emotional OR (95% CI) 1.07 (1.02–1.12). AUC 0.723; R2N 0.17; Hosmer-Lemeshow 0.815. Internal validation AUC 0.706.; R2N 0.134 Conclusion This is a simple model to predict hospitalization over a 12-month period based on four variables: NYHA functional class, diabetes, COPD and the emotional dimension of the MLHFQ scale. It has an acceptable discriminative capacity enabling the identification of patients at risk of hospitalization., This study was financed by the Health Research Fund (FIS), grant no. PI 14/01677 and co-financed with ERDF funds from the European Union: REDISSEC - Project ISCIII (Red de Investigación en Enfermedades Crónicas del Servicio de Salud - Instituto de Salud Carlos III) concession no. RD16/0001/0004. The Foundation for Biosanitary Research and Innovation in Primary Health Care (FIIBAP) financed the costs of publishing the article

Published
2019

35. Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer

Author

Zugazagoitia, Jon, primary, Biosca, Mercedes, additional, Oliveira, Julio, additional, Olmedo, María Eugenia, additional, Dómine, Manuel, additional, Nadal, Ernest, additional, Ruffinelli, José Carlos, additional, Muñoz, Nerea, additional, Luna, Ana María, additional, Hernández, Berta, additional, Martínez, Maite, additional, Gallego, Iria, additional, Martínez de Castro, Eva, additional, Font, Carme, additional, Calvo, Virginia, additional, Martínez-Marín, Virginia, additional, Corral, Jesús, additional, Noguerón, Esther, additional, Mondéjar, Rebeca, additional, García Escobar, Ignacio, additional, Salvador-Coloma, Carmen, additional, Juan, Óscar, additional, Sánchez Cánovas, Manuel, additional, Valdivia, Javier, additional, Ochoa, M. Pilar, additional, López Castro, Rafael, additional, Obispo, Berta, additional, Pangua, Cristina, additional, Sereno, María, additional, Fernández Franco, Lourdes, additional, Mielgo, Xabier, additional, Calzas, Julia, additional, Blasco, Ana, additional, Aparisi, Francisco, additional, Chara, Luis, additional, Grau, Juan Francisco, additional, Soares, Marta, additional, Gómez, Ana, additional, Zenzola, Victor, additional, García-Morillo, Marcial, additional, Cacho, Diego, additional, Díaz-Serrano, Asunción, additional, Aguado, Carlos, additional, Ponce-Aix, Santiago, additional, González-Larriba, Jose Luis, additional, Muñoz, Andrés J., additional, Lora, David, additional, Paz-Ares, Luis, additional, and Manzano, Aránzazu, additional

Published
2018
Full Text
View/download PDF

37. Whole-body imaging of lymphovascular niches identifies pre-metastatic roles of midkine

Author

Ministerio de Economía y Competitividad (España), Asociación Española Contra el Cáncer, Worldwide Cancer Research, Melanoma Research Alliance (US), L'Oréal, Instituto de Salud Carlos III, Ministerio de Sanidad, Servicios Sociales e Igualdad (España), Instituto Nacional del Cáncer (España), Icahn School of Medicine at Mount Sinai, Arc Foundation, Fundación Científica Asociación Española Contra el Cáncer, Fundación la Caixa, European Commission, Olmeda, David, Cerezo-Wallis, Daniela, Riveiro-Falkenbach, Erica, Pennacchi, Paula C., Contreras-Alcalde, Marta, Ibarz, Nuria, Cifdaloz, Metehan, Catena, Xavier, Calvo, Tonantzin G., Cañón, Estela, Alonso-Curbelo, Direna, Suarez, Javier, Osterloh, Lisa, Graña-Castro, Osvaldo, Mulero, Francisca, Megías, Diego, Cañamero, Marta, Martínez-Torrecuadrada, Jorge Luis, Mondal, Chandrani, Di Martino, Julie, Lora, David, Martinez-Corral, Inés, Bravo-Cordero, José J., Muñoz, Javier, Puig, Susana, Ortiz-Romero, Pablo, Rodriguez-Peralto, José L., Ortega, Sagrario, Soengas, María S., Ministerio de Economía y Competitividad (España), Asociación Española Contra el Cáncer, Worldwide Cancer Research, Melanoma Research Alliance (US), L'Oréal, Instituto de Salud Carlos III, Ministerio de Sanidad, Servicios Sociales e Igualdad (España), Instituto Nacional del Cáncer (España), Icahn School of Medicine at Mount Sinai, Arc Foundation, Fundación Científica Asociación Española Contra el Cáncer, Fundación la Caixa, European Commission, Olmeda, David, Cerezo-Wallis, Daniela, Riveiro-Falkenbach, Erica, Pennacchi, Paula C., Contreras-Alcalde, Marta, Ibarz, Nuria, Cifdaloz, Metehan, Catena, Xavier, Calvo, Tonantzin G., Cañón, Estela, Alonso-Curbelo, Direna, Suarez, Javier, Osterloh, Lisa, Graña-Castro, Osvaldo, Mulero, Francisca, Megías, Diego, Cañamero, Marta, Martínez-Torrecuadrada, Jorge Luis, Mondal, Chandrani, Di Martino, Julie, Lora, David, Martinez-Corral, Inés, Bravo-Cordero, José J., Muñoz, Javier, Puig, Susana, Ortiz-Romero, Pablo, Rodriguez-Peralto, José L., Ortega, Sagrario, and Soengas, María S.

Abstract

Cutaneous melanoma is a type of cancer with an inherent potential for lymph node colonization, which is generally preceded by neolymphangiogenesis1,2,3. However, sentinel lymph node removal does not necessarily extend the overall survival of patients with melanoma4,5. Moreover, lymphatic vessels collapse and become dysfunctional as melanomas progress6,7. Therefore, it is unclear whether (and how) lymphangiogenesis contributes to visceral metastasis. Soluble and vesicle-associated proteins secreted by tumours and/or their stroma have been proposed to condition pre-metastatic sites in patients with melanoma8,9,10,11,12,13,14. Still, the identities and prognostic value of lymphangiogenic mediators remain unclear2,14. Moreover, our understanding of lymphangiogenesis (in melanomas and other tumour types) is limited by the paucity of mouse models for live imaging of distal pre-metastatic niches15. Injectable lymphatic tracers have been developed7, but their limited diffusion precludes whole-body imaging at visceral sites16. Vascular endothelial growth factor receptor 3 (VEGFR3) is an attractive ‘lymphoreporter’17 because its expression is strongly downregulated in normal adult lymphatic endothelial cells, but is activated in pathological situations such as inflammation and cancer17,18. Here, we exploit this inducibility of VEGFR3 to engineer mouse melanoma models for whole-body imaging of metastasis generated by human cells, clinical biopsies or endogenously deregulated oncogenic pathways. This strategy revealed early induction of distal pre-metastatic niches uncoupled from lymphangiogenesis at primary lesions. Analyses of the melanoma secretome and validation in clinical specimens showed that the heparin-binding factor midkine is a systemic inducer of neo-lymphangiogenesis that defines patient prognosis. This role of midkine was linked to a paracrine activation of the mTOR pathway in lymphatic endothelial cells. These data support the use of VEGFR3 reporter mice as a ‘Me

Published
2017

38. Herpes zoster in kidney transplant recipients: protective effect of anti-cytomegalovirus prophylaxis and natural killer cell count. A single-center cohort study

Author

Fernández-Ruiz, Mario, primary, Origüen, Julia, additional, Lora, David, additional, López-Medrano, Francisco, additional, González, Esther, additional, Polanco, Natalia, additional, San Juan, Rafael, additional, Ruiz-Merlo, Tamara, additional, Parra, Patricia, additional, Andrés, Amado, additional, and Aguado, José María, additional

Published
2017
Full Text
View/download PDF

46. Agreement Between Computed Tomography and Pathologic Nodule Counts in Colorectal Lung Metastases

Author

Marron, M. Carmen, primary, Lora, David, additional, Gamez, Pablo, additional, Rivas, Juan J., additional, Embun, Raul, additional, Molins, Laureano, additional, de la Cruz, Javier, additional, Rivas, J.J., additional, Molins, L., additional, Embun, R., additional, Ruiz, J., additional, Pagés, C., additional, Cruz, J., additional, Freixinet, J., additional, Carbajo, M., additional, Rombolá, C., additional, Heras, F., additional, Mier, J.M., additional, Rivas, F., additional, Rodríguez, A., additional, Canalís, E., additional, Rubio, M., additional, Call, S., additional, Fernández, E., additional, Garcia, S., additional, Garcia, J.M., additional, González, D., additional, Blanco, M., additional, Jarabo, J.R., additional, Peñalver, R., additional, Muñoz, G., additional, Marrón, M.C., additional, Olaiz, B., additional, Arroyo, A., additional, Tamura, A., additional, Wins, R., additional, Arnau, A., additional, Córcoles, J.M., additional, Carriquiry, G., additional, Rosenberg, M., additional, and Smith, D., additional

Published
2016
Full Text
View/download PDF

47. Infusión lipídica en el tratamiento de intoxicaciones en humanos

Author

Vicente Lora, David, Dueñas Laita, Antonio, and Universidad de Valladolid. Facultad de Medicina

Subjects
Emulsión lipídica
Abstract

Los objetivos de esta revisión sistemática es hacer un resumen y revisar todos los estudios que se han proporcionado hasta ahora sobre la infusión lipidica como tratamiento de intoxicación. Aunque el nivel de evidencia científica y de estudio es muy reciente, este tipo de emulsiones lipídicas tienen un papel muy importante en el tratamiento de intoxicaciones. También uno de los objetivos que se hace sobre esta revisión sistemática es la de estudiar y examinar los aspectos farmacológicos y cinéticas de la emulsión lipidica para el uso intravenoso. Aparte del uso que tiene en la reanimación de la cardiotoxicidad de los anestésicos orales, también tiene un uso muy importante en los últimos años en los efectos tóxicos sobre el aparato cardiovascular y efectos patológicos en el aparato respiratorio o efectos tóxicos de algunos fármacos como la amitriptilina, olanzapina o cloroquina., Departamento de Medicina, Dermatología y Toxicología, Grado en Nutrición Humana y Dietética

Published
2013

48. Impact of MBL2gene polymorphisms on the risk of infection in solid organ transplant recipients: A systematic review and meta-analysis

Author

Fernández-Ruiz, Mario, Giménez, Estela, Lora, David, Aguado, José María, Pascual, Manuel, and Manuel, Oriol

Abstract

Mannose-binding lectin (MBL) is a soluble pattern recognition molecule involved in complement activation. Single nucleotide polymorphisms (SNPs) in the MBL2gene have been associated with susceptibility to infection, although data in solid organ transplant recipients remains inconclusive. This meta-analysis was primarily aimed at investigating the association between posttransplant bacterial and fungal infection and variant alleles of MBL2gene SNPs in the promoter/5’ untranslated region and exon 1. Cytomegalovirus (CMV) infection and/or disease were considered secondary outcomes. PubMed, EMBASE, and Web of Knowledge were searched for relevant articles up to August 2018. Eleven studies (comprising 1858 patients) were included, with liver transplant (LT) recipients accounting for 80.4% of the pooled population. As compared to high-MBL expression haplotypes (YA/YA, YA/XA), any MBL-deficient haplotype was associated with an increased risk of posttransplant bacterial and fungal infections (risk ratio [RR]: 1.30; P= .04). Low/null-MBL expression haplotypes (XA/O, O/O) also increased the risk of primary outcome (RR: 1.51; P= .008) and CMV events (RR: 1.50; P= .006). No effect was observed for individual promoter SNPs. In conclusion, MBL-deficient haplotypes are associated with a significant, albeit moderate, increase in the risk of posttransplant infection, with this association being mainly restricted to LT recipients.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results